This week PharmaShots’ news was all about the updates on M&A, Pharma, Clinical Trials, Regulatory & MedTech. Check out our full report below:

Cybin Reports Initiation of the P-II Clinical Evaluation of CYB004 for the Treatment of Generalized Anxiety Disorder

Read More: Cybin                                                                                                                              

GSK Features Results from the P-III (RUBY) Study of Jemperli to Treat Endometrial Cancer at Society of Gynecologic Oncology 2024

Read More: GSK                                                                                                                              

Asieris Highlights the P-III Study Data of APL-1702 for Treating Cervical High-Grade Squamous Intraepithelial Lesions at the 2024 EUROGIN Congress and SGO Annual Meeting

Read More: Asieris Pharmaceuticals                                                                                             

AstraZeneca Features the P-III (DUO-E) Study Results Evaluating Imfinzi for the Treatment of Endometrial Cancer at SGO 2024

Read More: AstraZeneca                                                                                                  

Innovent Highlights the P-II Study Results of IBI302 to Treat Neovascular Age-related Macular Degeneration (nAMD)

Read More: Innovent                                                                                                                              

Bayer Reveals the P-III (OASIS 3) Trial Results of Elinzanetant to Treat Vasomotor Symptoms in Postmenopausal Women

Read More: Bayer                                                                                                                              

Jasper Therapeutics Doses First Patient with Briquilimab in the P-Ib/IIa Study to Treat Chronic Inducible Urticaria

Read More: Jasper Therapeutics                                                                      

Merck Features Data from a Series of P-III Trials Assessing V116 Vaccine for Pneumococcal Diseases at ISPPD-13 2024

Read More: Merck                                                                                                                              

Merck Reports P-III (KEYLYNK-006) Study Results of Keytruda to Treat Metastatic Non-squamous NSCLC

Read More: Merck                                                                                                                              

Molecure Doses First Patient with OATD-01 in the P-II (KITE) Trial for Treating Pulmonary Sarcoidosis Across the UK 

Read More: Molecure                                                                                                                              

AstraZeneca Reports Results from the P-III (FLAURA2) Trial of Tagrisso Plus Chemotherapy to Treat Advanced Lung Cancer

Read More: AstraZeneca                                                                      

The US FDA Grants Approval to Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for Treating NASH with Liver Fibrosis

Read More: Madrigal Pharmaceuticals                                                                                     

The US FDA’s ODAC Recommends Johnson & Johnson’s Carvykti for the Treatment of Relapsed/Refractory Multiple Myeloma

Read More: Johnson & Johnson                                                                                                             

The US FDA Grants Approval to Orchard Therapeutics’ Lenmeldy for Treating Metachromatic Leukodystrophy

Read More: Orchard Therapeutics                                                                                                          

Health Canada Accepts for Review Biogen Canada’s New Drug Submission of Tofersen for the Treatment of Amyotrophic Lateral Sclerosis

Read More: Biogen              

The EC Grants Approval to BMS’ Abecma for the Treatment of Relapsed/Refractory Multiple Myeloma

Read More: BMS                                       

The US FDA Grants Orphan Drug Designation to Cabaletta Bio’s CABA-201 for Treating Systemic Sclerosis

Read More: Cabaletta Bio                                                                                             

The US FDA Approves Italfarmaco’s Duvyzat (givinostat) for Treating Duchenne Muscular Dystrophy

Read More: Italfarmaco                                                                                        

Fennec Pharmaceuticals and Norgine Join Forces to Commercialize Pedmarqsi in the EU, Australia and New Zealand

Read More: Fennec Pharmaceuticals & Norgine                                                                                

Sanyou Bio Partners with BioGeometry to Develop AIGC Driven Antibody Drug Discovery Platform 

Read More: Sanyou Bio & BioGeometry                                                                                         

Bio-Thera Solutions and SteinCares Join Forces for Marketing Biosimilars Across LATAM

Read More: Bio-Thera Solutions & SteinCares                                                                                   

Evommune Expands its Partnership with Maruho for the Development and Commercialization of EVO756 in Greater China and Asian Countries

Read More: Evommune & Maruho                                                                                                 

Bayer and Thermo Fisher Scientific Collaborate on NGS-Based Companion Diagnostic Assays (CDx)

Read More: Bayer & Thermo Fisher Scientific                                                                                 

Kazia Therapeutics Partners with Sovargen to Develop Paxalisib for the Treatment of Intractable Seizures in Rare CNS Diseases

Read More: Kazia Therapeutics & Sovargen                                                                                   

Relief Therapeutics Collaborates with Eton Pharmaceuticals to Commercialize Golike Products for Phenylketonuria

Read More: Relief Therapeutics & Eton Pharmaceuticals                                                               

The US FDA Grants Breakthrough Device Designation to Vicore’s Almee for Pulmonary Fibrosis

Read More: Vicore                               

The US FDA Grants 510(k) Clearance to inHEART’s AI-Based Software Module for Creating 3D Cardiac Models

Read More: inHEART                                 

Onymos and Vapotherm Collaborate for Developing an End-to-End Internet of Medical Things Solution (IoMT)

Read More: Onymos & Vapotherm                                                                                                  

TELA Bio Launches its LIQUIFIX FIX8 and LIQUIFIX Precision Devices for Internal Use in Hernia Surgery Across the US

Read More: TELA Bio                                                  

For an Aggregate of ~2.4B, AstraZeneca to Acquire Fusion Pharmaceuticals for the Development of Radioconjugates

Read More: AstraZeneca & Fusion Pharmaceuticals         

Related Post:- PharmaShots Weekly Snapshots (March 11 – March 15, 2024)